TY - JOUR
T1 - Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates
AU - Al Kaabi, Nawal
AU - Oulhaj, Abderrahim
AU - Ganesan, Subhashini
AU - Al Hosani, Farida Ismail
AU - Najim, Omer
AU - Ibrahim, Halah
AU - Acuna, Juan Manuel
AU - Alsuwaidi, Ahmed R.
AU - Kamour, Ashraf M.
AU - Alzaabi, Ashraf
AU - Al Shehhi, Badreyya Ahmed
AU - Al Safar, Habiba
AU - Hussein, Salah Eldin
AU - Abdalla, Jehad Saleh
AU - Al Mansoori, Dalal Saeed Naser
AU - Al Hammadi, Ahmed Abdul Kareem
AU - Amari, Mohammed A.
AU - Al Romaithi, Ahmed Khamis
AU - Weber, Stefan
AU - Elavalli, Santosh
AU - Eltantawy, Islam
AU - Alghaithi, Noura Khamis
AU - Al Azazi, Jumana Nafiz
AU - Holt, Stephen Geoffrey
AU - Mostafa, Mohamed
AU - Halwani, Rabih
AU - Khalak, Hanif
AU - Elamin, Wael
AU - Beiram, Rami
AU - Zaher, Walid
N1 - Funding Information:
We acknowledge the contribution of all individuals who helped in data collection and management.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - The effectiveness of the inactivated BBIBP-CorV vaccine against severe COVID-19 outcomes (hospitalization, critical care admission and death due to COVID-19) and its long-term effectiveness have not been well characterized among the general population. We conducted a retrospective cohort study using electronic health records of 3,147,869 adults, of which 1,099,886 vaccinated individuals were matched, in a 1:1 ratio to 1,099,886 unvaccinated persons. A Cox-proportional hazard model with time varying coefficients was used to assess the vaccine effectiveness adjusting for age, sex, comorbidity, ethnicity, and the calendar month of entry into the study. Our analysis showed that the effectiveness was 79.6% (95% CI, 77.7 to 81.3) against hospitalization, 86% (95% CI, 82.2 to 89.0) against critical care admission, and 84.1% (95% CI, 70.8 to 91.3) against death due to COVID-19. The effectiveness against these severe outcomes declined over time indicating the need for booster doses to increase protection against severe COVID-19 outcomes.
AB - The effectiveness of the inactivated BBIBP-CorV vaccine against severe COVID-19 outcomes (hospitalization, critical care admission and death due to COVID-19) and its long-term effectiveness have not been well characterized among the general population. We conducted a retrospective cohort study using electronic health records of 3,147,869 adults, of which 1,099,886 vaccinated individuals were matched, in a 1:1 ratio to 1,099,886 unvaccinated persons. A Cox-proportional hazard model with time varying coefficients was used to assess the vaccine effectiveness adjusting for age, sex, comorbidity, ethnicity, and the calendar month of entry into the study. Our analysis showed that the effectiveness was 79.6% (95% CI, 77.7 to 81.3) against hospitalization, 86% (95% CI, 82.2 to 89.0) against critical care admission, and 84.1% (95% CI, 70.8 to 91.3) against death due to COVID-19. The effectiveness against these severe outcomes declined over time indicating the need for booster doses to increase protection against severe COVID-19 outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85131706573&partnerID=8YFLogxK
U2 - 10.1038/s41467-022-30835-1
DO - 10.1038/s41467-022-30835-1
M3 - Article
C2 - 35680857
AN - SCOPUS:85131706573
SN - 2041-1723
VL - 13
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 3215
ER -
